Systematic Review and Network Meta-Analysis of Initial Treatments for Lupus Nephritis. (PubMed, Kidney Int Rep) - Sep 22, 2025 - "The network meta-analysis revealed that voclosporin (VCS) combined with MPAA (risk difference [RD]: 281.38 more/1000, 95% confidence interval [CI]: 146.26 more to 456.42 more; high certainty), belimumab (BEL) combined with MPAA (RD: 145.02 more/1000, 95% CI: 72.73 more to 230.92 more; high certainty), and obinutuzumab (OBI) combined with MPAA (RD: 134.23 more/1000, 95% CI: 30.37 more to 269.68 more; moderate certainty) increased complete renal response (CRR) compared with MPAA alone. Combination therapies, particularly VCS, BEL, or OBI with MPAA, provide enhanced outcomes for LN initial treatment. Given the complexity of LN, clinicians should weigh these findings alongside considerations such as drug availability, cost, and individual patient preferences to guide treatment decisions."
Journal • Retrospective data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology
|
|
; Agustín Bengolea; Ana Malvar; Ariel Izcovich; Bernardo A Pons-Estel; Camila Agnoletti; Carlos Enrique Toro-Gutiérrez; Edgard Torres Dos Reis-Neto; Eduardo F Borba; Eloisa Bonfá; Fernando Tortosa; Graciela S Alarcón; Guillermo Pons-Estel; Hilda Fragoso Loyo; Jorge A Esquivel-Valerio; Jose A Gómez-Puerta; Juan Manuel Mejía-Vilet; Loreto Massardo; Manuel F Ugarte-Gil; Mariano Fielli; Marina Scolnik; Martín Ragusa; Moira Magdalena Pissinis; Odirlei Andre Monticielo; Rosana Quintana
|